Clinical trials: Viral Pneumonia
SARS-CoV-2 (Covid19)
Safety and Efficacy of Trans Sodium Crocetinate (TSC) in SARS-CoV-2 (COVID-19) Infected Subjects
This study will assess the safety and efficacy of TSC as a treatment for participants who are infected with SARS-CoV-2 (COVID-19).
- Trial name
- NCT04573322
- Testing
- Trans Sodium Crocetinate, Normal saline
- Where
- Romania
- Volunteers
- 25 people
- Sponsor
- Diffusion Pharmaceuticals Inc
SARS-CoV-2 Infection
Evusheld Japan PMS_Japan Post-Marketing Surveillance (PMS)
To investigate intends to evaluate the incidence of adverse drug reactions (ADRs) in individuals who receive Evusheld in clinical practice to determine its post-marketing safety profile in Japanese.
- Trial name
- NCT05687877
- Where
- 18 sites in Japan
- Volunteers
- 366 people
- Sponsor
- AstraZeneca
Covid19
Retrospective Study of ImmunoFormulation for COVID-19
Multicentre, retrospective, observational study to describe the course of SARS-CoV-2 disease in patients treated or not with IMUNO TF ® and a combination of nutraceuticals and who have tested positive in a COVID-19 diagnostic…
- Trial name
- NCT04666753
- Testing
- ImmunoFormulation
- Where
- 2 sites in Spain
- Volunteers
- 40 people
- Sponsor
- Fagron Iberica S.A.U.
Healthy Subjects
A Study to Explore the Physiological Impact of AIR+ KN95 Masks on Children
The primary objective is to evaluate the physiological impact of AIR+ KN95 Masks on end-tidal carbon dioxide (ETCO2) of children aged 7 to 14 years of age.
- Trial name
- NCT07037381
- Testing
- KN95 mask
- Where
- Singapore
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Innosparks Pte Ltd.
COVID-19
Safety and Immunogenicity Study of Booster Vaccination With Medium-dosage or High-dosage SARS-CoV-2 Inactivated Vaccine for Prevention of COVID-19
This is a randomized, double-blinded, phase ⅠV clinical trial of SARS-CoV-2 inactivated vaccine manufactured by manufactured by Sinovac Research \& Development Co., Ltd.
- Trial name
- NCT05079217
- Testing
- High-dosage SARS-CoV-2 vaccine, Medium-dosage SARS-CoV-2 vaccine
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
COVID-19, Lung Infection
Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia
A phase 2/3 multi-center randomized, double-blind, parallel arm, placebo- controlled study in Adult Subjects Hospitalized with Severe SARS-CoV-2 Positive Pneumonia to determine the potential of opaganib to improve and/or…
- Trial name
- NCT04467840
- Testing
- Opaganib
- Where
- 57 sites in United States, Brazil and 8 more
- Volunteers
- 475 people
- Sponsor
- RedHill Biopharma Limited
SARS-CoV-2, COVID-19
Clinical Evaluation of the VitaSIRO Solo™ Respiratory Assay
The purpose of this clinical trial is to demonstrate the clinical performance of the VitaSIRO solo™ SARS-CoV-2/Flu/RSV Assay in detecting SARS-CoV-2, Flu A, Flu B and RSV in symptomatic population.
- Conditions
- SARS-CoV-2, COVID-19, RSV, Influenza
- Trial name
- NCT06689423
- Testing
- Credo POCT Device
- Where
- Taiwan
- Volunteers
- 1,268 people
- Sponsor
- Credo Diagnostics Biomedical Pte. Ltd.
COVID-19 Pandemic
Clinical Study for Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Immunization
A Clinical Study to Evaluate the Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Against COVID-19 in Healthy Adults Aged 18 Years and Older After the Vaccination of 2…
- Trial name
- COVID-19 (NCT05125874)
- Testing
- Recombinant SARS-CoV-2 Fusion Protein Vaccine
- Where
- China
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Livzon Pharmaceutical Group Inc.
COVID-19
Immunogenicity and Safety of a Booster Dose of the SpikoGen COVID-19 Vaccine
This was a randomized, two-armed, double-blind, placebo-controlled trial designed to evaluate the safety and immunogenicity of a booster dose of an adjuvanted recombinant SARS-CoV-2 spike protein subunit vaccine (SpikoGen)…
- Trial name
- NCT05175625
- Testing
- SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant
- Where
- Iran
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Cinnagen
Covid19
Measurement of Viral Load Reduction in the Oral Cavity After a Regimental Use of OC Toothpaste Products
SARS COVID 2 has caused a pandemic of proportions unparalleled in the past 100 years. The virus has an uncanny ability for transmission and as such has been difficult to control.
- Trial name
- NCT04864925
- Testing
- Colgate Total Clean Mint, Tom's Botanically Bright Peppermint
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Colgate Palmolive
Covid-19
Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19
This is an exploratory study to evaluate the efficacy of hydroxychloroquine (400 mg BID on D1 and 400 mg/day on D2 to D7) and azithromycin (500 mg/ 5 days) to treat mild ambulatory COVID-19 patients.
- Trial name
- NCT04348474
- Testing
- Hydroxychloroquine Sulfate, Azithromycin Tablets
- Where
- Brazil
- Volunteers
- 200 people
- Sponsor
- Azidus Brasil
Acute Lung Injury (ALI) Due to Coronavirus Disease-2019 (COVID-19)
TD-0903 Pharmacokinetics Study in Healthy Participants With Supplemental Oxygenation
This is a Phase 1 pharmacokinetic (PK) study in healthy participants to assess the plasma pharmacokinetics, safety, and tolerability of a single inhaled dose of nezulcitinib (TD-0903) with supplemental oxygenation.
- Trial name
- NCT05091723
- Testing
- Nezulcitinib (TD-0903) Dose A, Nezulcitinib (TD-0903) Dose B
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Theravance Biopharma
Long COVID, Post-COVID Syndrome
Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients with Post-COVID Syndrome
REGENECYTE (HPC, Cord Blood, hUCB) for treatment in patients with post-COVID.
- Conditions
- Long COVID, Post-COVID Syndrome, Post COVID-19 Condition
- Trial name
- NCT05682560
- Testing
- REGENECYTE
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- StemCyte, Inc.
Covid19, SARS-COV-2 Infection
A Study of DWJ1248 in Prevention of COVID-19 Infection After the Exposure of SARS-COV-2
To evaluate the prevention of SARS-COV-2 infection after administration of DWJ1248 in person who contact from COVID-19 confirmed patient compared to the placebo.
- Trial name
- NCT04721535
- Testing
- DWJ1248
- Where
- South Korea
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Influenza Infection, SAD-RV Infection and COVID-19
DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19)
This is a Phase IIb study consisting of two cohorts to evaluate efficacy, safety and pharmacokinetics of DAS181 in IFV infection. An approximate total of 280 subjects will be enrolled into this study.
- Trial name
- STOP-Flu (NCT04298060)
- Testing
- DAS181
- Where
- China
- Volunteers
- 280 people
- Sponsor
- Ansun Biopharma, Inc.
Covid19
Study of Codivir in Patients With COVID-19
This is an open-label study to evaluate the safety and preliminary efficacy of Codivir in 12 mild or moderate COVID-19 patients and onset of symptoms within 72h prior to their inclusion.
- Trial name
- Codivir (NCT04930861)
- Testing
- Covidir injections, One Step Test, IgM and IgG dosage
- Where
- Brazil
- Volunteers
- 12 people
- Sponsor
- Code Pharma
COVID-19, SARS-CoV-2 Infection
A Trial Investigating the Safety and Effects of One or Two Additional Doses of Comirnaty or One Dose of BNT162b2s01 in BNT162-01 or BNT162-04 Trial Subjects
Trial to evaluate the safety and immunogenicity of one or two boosting doses of Comirnaty or one dose of BNT162b2s01 (Variant of concern [VOC] strain B.1.351) in BNT162-01 trial participants, or two boosting doses of Comirnaty in…
- Trial name
- NCT04949490
- Testing
- BNT162b2s01, BNT162b2
- Where
- 4 sites in Germany
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Healthy
Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of ZYIL1 Following Oral Administration in Healthy Volunteers
ZYIL1 is a novel oral selective NLRP3 inflammasome inhibitor which prevents NLRP3-induced ASC oligomerization, thus inhibiting NLRP3 inflammasome pathway.
- Trial name
- NCT04731324
- Testing
- ZYIL1 capsule
- Where
- India
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Zydus Lifesciences Limited
COVID-19
Phase I/II Clinical Trial of Recombinant Novel Coronavirus (COVID-19) Vaccine (Adenovirus Type 5 Vector) for Inhalation
This study is a randomized, double-blind, placebo-controlled I/II clinical trial, in order to evaluate the safety and immunogenicity of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation in adults 18…
- Trial name
- NCT04840992
- Testing
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation, Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
- Where
- China
- Volunteers
- 840 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
COVID-19, Coronavirus Infection
Piclidenoson for Treatment of COVID-19
Patients with documented moderate COVID-19 infection will be randomized 1:1 to receive piclidenoson 2 mg Q12H orally with standard supportive care (SSC - intervention arm) or placebo orally with SSC (control arm) for up to 28…
- Trial name
- NCT04333472
- Testing
- Piclidenoson
- Where
- 6 sites in Bulgaria, Israel and 1 more
- Volunteers
- 6 people
- Sponsor
- Can-Fite BioPharma
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.